Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for untreated unresectable malignant pleural mesothelioma.
 
Status In progress
Process STA 2018
ID number 1609

Provisional Schedule

Committee meeting: 2 07 October 2021
Expected publication 13 October 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab, ipilimumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Mesothelioma UK
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  =

Commentators

Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
27 August 2021 - 20 September 2021 Appraisal consultation: 1
04 August 2021 Committee meeting: 1
21 January 2021 Please note that due to operational issues the timelines for this appraisal have now been updated. Therefore, the appraisal committee meeting for this topic has been rescheduled. The technical engagement period for this appraisal is now scheduled to start in mid-April 2021. The new committee date will be Wednesday 4 August 2021.
29 September 2020 Invitation to participate
06 August 2020 - 04 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
12 May 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. Please note that following on from advice received from the company the timelines for this appraisal have been revised and we now anticipate that the appraisal will begin during late September 2020 when we will write to you about how you can get involved.
16 September 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late July- 2020 when we will write to you about how you can get involved.
06 August 2019 - 04 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress. Referred 31 July 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance